Table 2.
Demographic and Clinical Features of Patients with WM-Ls with a Rim of elevated R2*
| Age | Sex | MS Years | MS Type | EDSS | Disease Modifying Therapy | |
|---|---|---|---|---|---|---|
| Pt-1 | 40 | Male | .9 | RRMS | 1.0 | None |
| Pt-2 | 40 | Male | 1.5 | RRMS | 2.5 | Interferon beta-1a |
| Pt-3 | 56 | Male | 25 | RRMS | 1.5 | Interferon beta-1b |
| Pt-4 | 44 | Female | 15 | RRMS | 1.0 | Interferon beta-1a |
| Pt-5 | 57 | Female | 33 | SPMS | 6.0 | None |
| Pt-6 | 30 | Female | 1.1 | RRMS | 1.5 | Interferon beta-1b |
| Pt-7 | 49 | Female | 20.1 | RRMS | 4.0 | Daclizumab |
| Pt-8 | 40 | Male | 7.5 | RRMS | 2.5 | Monthly methylprednisolone |
| Pt-9 | 49.5 | Male | 21.7 | RRMS | 2.0 | Daclizumab |
| Pt-10 | 38 | Male | 6 | RRMS | 1.0 | Interferon beta-1b |
EDSS = expanded disability stats scale; RR = relapsing remitting; SP = secondary progressive.